Shareholders of Harris & Harris Group, Inc., may be interested to know that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating BioVex's lead product, OncoVEXGM-CSF, in previously treated patients with metastatic melanoma. The agreement was made under the special Protocol Assessment (SPA) procedure. You may access BioVex's press release at http://www.biovex.com/22_04_08.htm.
Harris & Harris Group is a shareholder in privately held BioVex, Inc.
Harris & Harris Group is a publicly traded venture capital company that makes initial investments exclusively in tiny technology, including nanotechnology, microsystems and microelectromechanical systems (MEMS).
Detailed information about Harris & Harris Group and its holdings can be found on its website at www.TinyTechVC.com.
This news release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this news release. Please see the Company's Registration Statement on Form N-2 and Annual Report on Form 10-K for the year ended December 31, 2007, as well as subsequent SEC filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc., undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The reference to the websites www.TinyTechVC.com and www.biovex.com.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this news release.
CONTACT: DOUGLAS W. JAMISON
TEL. NO. (212) 582-0900